(0.06%) 5 334.75 points
(0.01%) 39 949 points
(-0.01%) 18 761 points
(-0.69%) $79.25
(0.69%) $2.77
(-0.62%) $2 423.30
(-1.62%) $31.90
(-1.37%) $1 049.10
(-0.03%) $0.920
(-0.12%) $10.68
(-0.07%) $0.786
(-0.33%) $90.38
Live Chart Being Loaded With Signals
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China...
Stats | |
---|---|
Dagens volum | 24 323.00 |
Gjennomsnittsvolum | 190 072 |
Markedsverdi | 3.42M |
EPS | $0 ( 2024-05-20 ) |
Neste inntjeningsdato | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.190 |
ATR14 | $0.00900 (2.92%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-11-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2021-05-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2022-05-01 | Tauzin W J | Buy | 8 000 | Stock Option right to buy) |
2022-11-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2022-01-01 | Tauzin W J | Buy | 4 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
99.83 |
Last 100 transactions |
Buy: 44 704 561 | Sell: 8 187 803 |
Avalon GloboCare Corp. Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Avalon GloboCare Corp. Økonomi
Annual | 2023 |
Omsetning: | $1.26M |
Bruttogevinst: | $202 789 (16.15 %) |
EPS: | $-1.590 |
FY | 2023 |
Omsetning: | $1.26M |
Bruttogevinst: | $202 789 (16.15 %) |
EPS: | $-1.590 |
FY | 2022 |
Omsetning: | $1.20M |
Bruttogevinst: | $272 728 (22.69 %) |
EPS: | $-1.360 |
FY | 2021 |
Omsetning: | $1.39M |
Bruttogevinst: | $414 518 (29.80 %) |
EPS: | $-1.100 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.